195 related articles for article (PubMed ID: 36860697)
1. Affordable Prices Without Threatening the Oncological R&D Pipeline-An Economic Experiment on Transparency in Price Negotiations.
Franzen N; Ziegler A; Romagnoli G; Retèl VP; Offerman TJS; van Harten WH
Cancer Res Commun; 2022 Jan; 2(1):49-57. PubMed ID: 36860697
[TBL] [Abstract][Full Text] [Related]
2. Confidentiality agreements: a challenge in market regulation.
Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
[TBL] [Abstract][Full Text] [Related]
3. Price comparison of high-cost originator medicines in European countries.
Vogler S; Zimmermann N; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
[TBL] [Abstract][Full Text] [Related]
4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
5. Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.
Shaw B; Mestre-Ferrandiz J
Pharmacoeconomics; 2020 Feb; 38(2):125-134. PubMed ID: 31956967
[TBL] [Abstract][Full Text] [Related]
6. Prices of new medicines: International analysis and policy options.
Vogler S
Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():96-102. PubMed ID: 36372642
[TBL] [Abstract][Full Text] [Related]
7. Evidence on the effectiveness of policies promoting price transparency - A systematic review.
Joosse IR; Tordrup D; Glanville J; Kotas E; Mantel-Teeuwisse AK; van den Ham HA
Health Policy; 2023 Aug; 134():104681. PubMed ID: 36372608
[TBL] [Abstract][Full Text] [Related]
8. Drug price transparency initiative: A scoping review.
Ahmad NS; Makmor-Bakry M; Hatah E
Res Social Adm Pharm; 2020 Oct; 16(10):1359-1369. PubMed ID: 31987771
[TBL] [Abstract][Full Text] [Related]
9. Enhancing medicine price transparency through price information mechanisms.
Hinsch M; Kaddar M; Schmitt S
Global Health; 2014 May; 10():34. PubMed ID: 24885767
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical net price transparency across european markets: Insights from a multi-agent simulation model.
Riccaboni M; Swoboda T; Van Dyck W
Health Policy; 2022 Jun; 126(6):534-540. PubMed ID: 35459584
[TBL] [Abstract][Full Text] [Related]
11. Review of studies reporting actual prices for medicines.
Mardetko N; Kos M; Vogler S
Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097
[TBL] [Abstract][Full Text] [Related]
12. Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia.
Morgan SG; Vogler S; Wagner AK
Health Policy; 2017 Apr; 121(4):354-362. PubMed ID: 28238340
[TBL] [Abstract][Full Text] [Related]
13. The economics of parallel trade.
Danzon PM
Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
[TBL] [Abstract][Full Text] [Related]
14. Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J; Lan T; Lu H; Pan J
PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
[TBL] [Abstract][Full Text] [Related]
15. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
16. Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China.
Zhang Y; Wei Y; Li H; Chen Y; Guo Y; Han S; Shi L; Guan X
Pharmacoeconomics; 2022 Jul; 40(7):715-724. PubMed ID: 35764914
[TBL] [Abstract][Full Text] [Related]
17. Drug pricing and transparency in Europe and the United States: what is it and how does it work?
Simoens S; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):477-486. PubMed ID: 38275164
[TBL] [Abstract][Full Text] [Related]
18. Can locally developed me-too drugs aid price negotiation? An example of cancer therapies from China.
Luo Z; Gyawali B; Han S; Shi L; Guan X; Wagner AK
Semin Oncol; 2021 Apr; 48(2):141-144. PubMed ID: 33875231
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
